VACCINE-ASSOCIATED MYOCARDITIS: INSIGHTS FROM THE CCS MYCOVACC SURVEILLANCE STUDY (CCC-109)

Thursday, October 26, 2023

09:45 – 10:30 EST

Location: Palais, 524C

Target Audience: General: All cardiovascular (clinical and research) health professionals, Pediatric cardiologists, Primary Care Physicians

Co-Chair(s)

Michael A. McDonald, MD

Cardiologist
CHFS
Toronto General Hospital
Carolyn Pullen, BNSc, RN, PhD (she/her/hers)

Chief Executive Officer
Canadian Cardiovascular Society

Presenter(s)

Nathaniel M. Hawkins, MBChB, MD, MPH

Associate Professor
CHFS
University of British Columbia
Michael Khoury, MD

Assistant Professor, Pediatric Cardiology, Department of Pediatrics
CPCA
University of Alberta
Tahir Kafil, MD, FRCPC

Advanced Clinical Fellow
Cleveland Clinic Foundation
Cleveland Clinic Foundation
Susanna Ogunnaike-Cooke (she/her/hers)

Executive Director
Public Health Agency of Canada

Planning Committee Member(s)

AS

Alexander Singer
Sean Virani, MD, MSc, MPH, FRCPC, FCCS (he/him/his)

Vice-President | Medical and Academic Affairs | Provincial Health Services Authority
UBC
St. Paul's Hospital | Providence Health Care
MW

Meredith Wright

Canadian Cardiovascular Society

Disclosure(s):

Michael A. McDonald, MD: BI-Lilly: Consultant/Advisory Board (Terminated, October 31, 2022); Novartis: Speaker/Honoraria (Terminated, October 1, 2022); Servier: Speaker/Honoraria (Terminated, December 1, 2022)

Carolyn Pullen: No financial relationships to disclose

Nathaniel M. Hawkins, MBChB, MD, MPH: No financial relationships to disclose

Tahir Kafil, MD, FRCPC: No financial relationships to disclose

Susanna Ogunnaike-Cooke: No financial relationships to disclose

Sean Virani, MD, MSc, MPH, FRCPC, FCCS: No financial relationships to disclose

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

apply current clinical guidance in the management and follow-up of patients with vaccine-associated myocarditis;
identify key knowledge gaps in the management and follow-up of patients with vaccine-associated myocarditis;
indicate when and how to report events following vaccination;
describe the scope and breadth of the MYCOVACC surveillance study and how to participate in the study and refer patients; and
locate key resources for additional information on vaccine-associated myocarditis in Canada.

Workshop Description: Myocarditis after mRNA COVID-19 vaccination is rare, and most cases are mild and self-limiting; however, the longer-term health and functional implications of the acute myocardial injury are uncertain. This knowledge gap can impact confidence in vaccines, particularly for young adults and children. In this context, the Public Health Agency of Canada funded the Canadian Cardiovascular Society to initiate a pan-Canadian study to examine the outcomes of a cohort of patients with myocarditis and/or pericarditis following mRNA COVID-19 vaccination. This session will update the Canadian cardiovascular community on the National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC). We will review current clinical guidance about the management of vaccine-associated myocarditis using an illustrative clinical vignette. Vaccine safety surveillance in Canada will be presented as well as current Canadian surveillance data on myocarditis/pericarditis. MYCOVACC national surveillance study progress will be described including partner sites, participant recruitment and early results. Participants will have an opportunity to explore ways of further engaging in the project.